| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
183,565 |
138,008 |
$5.90M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
118,129 |
94,518 |
$4.99M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
120,294 |
47,183 |
$2.81M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
43,884 |
28,719 |
$2.35M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
18,811 |
14,105 |
$1.64M |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
22,846 |
8,897 |
$438K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
8,620 |
6,820 |
$359K |
| 97161 |
|
6,366 |
5,470 |
$293K |
| 64483 |
|
2,859 |
2,085 |
$265K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
15,040 |
6,506 |
$256K |
| 20610 |
|
9,293 |
7,138 |
$200K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
13,538 |
5,189 |
$191K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
1,719 |
1,310 |
$157K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
1,355 |
1,107 |
$129K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
4,783 |
3,510 |
$108K |
| 73630 |
|
5,749 |
3,898 |
$74K |
| 73110 |
|
3,968 |
2,289 |
$65K |
| 95886 |
|
1,478 |
1,102 |
$61K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
21,325 |
16,121 |
$53K |
| 73562 |
|
2,899 |
2,233 |
$47K |
| 73610 |
|
2,958 |
2,076 |
$46K |
| 73130 |
|
3,315 |
2,108 |
$46K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,358 |
715 |
$42K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,021 |
792 |
$40K |
| A4590 |
Special casting material (e.g., fiberglass) |
2,713 |
1,681 |
$37K |
| 27096 |
|
611 |
424 |
$37K |
| 95911 |
|
344 |
260 |
$31K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
18,574 |
9,401 |
$30K |
| 72100 |
|
1,517 |
1,302 |
$24K |
| 72110 |
|
814 |
711 |
$20K |
| 80305 |
|
2,350 |
1,991 |
$18K |
| 99215 |
Prolong outpt/office vis |
338 |
277 |
$17K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
64 |
51 |
$15K |
| 73140 |
|
933 |
636 |
$14K |
| 20611 |
|
384 |
256 |
$12K |
| 97016 |
|
1,572 |
673 |
$10K |
| L4361 |
Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated, off-the-shelf |
71 |
61 |
$10K |
| 76942 |
|
269 |
141 |
$10K |
| 73560 |
|
971 |
715 |
$7K |
| 73564 |
|
400 |
331 |
$7K |
| 62321 |
|
87 |
67 |
$7K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
1,427 |
868 |
$7K |
| 99051 |
|
252 |
237 |
$6K |
| 62323 |
|
110 |
91 |
$5K |
| 76882 |
|
245 |
179 |
$5K |
| 73100 |
|
344 |
226 |
$5K |
| 64493 |
|
140 |
101 |
$5K |
| L3908 |
Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf |
248 |
154 |
$5K |
| 20550 |
|
438 |
207 |
$5K |
| 99243 |
|
44 |
43 |
$4K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
2,163 |
1,536 |
$4K |
| 95909 |
|
73 |
53 |
$4K |
| 29075 |
|
71 |
52 |
$3K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
13 |
12 |
$3K |
| L4387 |
Walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated, off-the-shelf |
42 |
42 |
$3K |
| 77002 |
|
123 |
92 |
$3K |
| 99442 |
|
89 |
74 |
$3K |
| 73030 |
|
267 |
204 |
$3K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
16 |
14 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
5,385 |
3,838 |
$2K |
| 64494 |
|
137 |
98 |
$2K |
| 97165 |
|
46 |
37 |
$2K |
| 20552 |
|
130 |
109 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
258 |
214 |
$2K |
| 97010 |
|
1,038 |
512 |
$2K |
| A9585 |
Injection, gadobutrol, 0.1 ml |
184 |
138 |
$1K |
| L3809 |
Wrist hand finger orthosis, without joint(s), prefabricated, off-the-shelf, any type |
13 |
13 |
$1K |
| 73600 |
|
144 |
94 |
$1K |
| 96160 |
|
908 |
459 |
$1K |
| 97535 |
Self-care/home management training, each 15 minutes |
176 |
149 |
$1K |
| 64495 |
|
60 |
42 |
$1K |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
303 |
258 |
$934.54 |
| J0897 |
Injection, denosumab, 1 mg |
16 |
12 |
$826.20 |
| 72040 |
|
38 |
38 |
$824.38 |
| 99443 |
|
34 |
28 |
$805.15 |
| J3490 |
Unclassified drugs |
7,390 |
5,163 |
$613.84 |
| 29105 |
|
12 |
12 |
$605.84 |
| 72170 |
|
118 |
100 |
$604.31 |
| 72082 |
|
14 |
14 |
$559.49 |
| 73502 |
|
88 |
53 |
$550.32 |
| 97035 |
|
111 |
58 |
$482.31 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
230 |
84 |
$450.74 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
350 |
131 |
$372.36 |
| 11721 |
|
93 |
70 |
$278.33 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
124 |
115 |
$267.51 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
36 |
29 |
$262.27 |
| 99406 |
|
47 |
28 |
$259.49 |
| 73565 |
|
36 |
27 |
$197.86 |
| 73501 |
|
24 |
14 |
$183.06 |
| 97022 |
|
41 |
12 |
$137.58 |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
113 |
57 |
$66.58 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
91 |
79 |
$61.38 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
13 |
12 |
$57.22 |
| 36415 |
Collection of venous blood by venipuncture |
14 |
12 |
$27.00 |
| 82962 |
|
22 |
12 |
$11.80 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
13 |
12 |
$0.00 |